Literature DB >> 18410603

Liver stem cells: a scientific and clinical perspective.

Yock Young Dan1, George C Yeoh.   

Abstract

The promise of liver stem cells lie in their potential to provide a continual and readily available source of liver cells that can be used for gene therapy, cellular transplant, bioartificial liver-assisted devices, drug toxicology testing and use as an in vitro model to understand the developmental biology of the liver. Both the rodent and human embryonic stem cell, bone marrow hematopoietic stem cell, mesenchymal stem cell, umbilical cord blood cell, fetal liver progenitor cell, adult liver progenitor cell as well as the mature hepatocyte have been reported to be capable of self-renewal, giving rise to daughter hepatocytes both in vivo and in vitro. These cells can repopulate livers in animal models of liver injury and seemingly improve liver function. However, significant challenges still exist before these cells can be used in humans. These include lack of consensus in immunophenotype of liver progenitor cells, uncertainty of the physiological role of reported candidate stem/progenitor cell, practicality in obtaining sufficient quantity of cells for clinical use and concerns over ethics, long-term efficacy and safety. Current molecular techniques of stem cell identification are confounded by cell fusion, horizontal gene transfer, incomplete differentiation and fetal microchimerism. Reports of stem cell transplantation and phase 1 trials of bone marrow transplantation in humans for liver diseases are exciting but require more robust verification. We review the evidence for various candidate stem cells, human clinical trials reported to date and highlight the challenges facing clinicians in their quest to use liver stem cells to save lives.

Entities:  

Mesh:

Year:  2008        PMID: 18410603     DOI: 10.1111/j.1440-1746.2008.05383.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

1.  New concepts in liver regeneration.

Authors:  Kimberly J Riehle; Yock Y Dan; Jean S Campbell; Nelson Fausto
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

Review 2.  Cellular models for disease exploring and drug screening.

Authors:  Zhi-Kun Li; Qi Zhou
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

3.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

4.  Treatment of newborn G6pc(-/-) mice with bone marrow-derived myelomonocytes induces liver repair.

Authors:  Roberta Resaz; Laura Emionite; Cristina Vanni; Simonetta Astigiano; Maura Puppo; Rosa Lavieri; Daniela Segalerba; Annalisa Pezzolo; Maria Carla Bosco; Alessandra Oberto; Carola Eva; Janice Y Chou; Luigi Varesio; Ottavia Barbieri; Alessandra Eva
Journal:  J Hepatol       Date:  2011-04-13       Impact factor: 25.083

Review 5.  Therapeutic potential of stem cell in liver regeneration.

Authors:  Jinzheng Li; Min Li; Bolin Niu; Jianping Gong
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

Review 6.  Role of liver stem cells in hepatocarcinogenesis.

Authors:  Lei-Bo Xu; Chao Liu
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

7.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.

Authors:  Kwang-Pyo Lee; Joo-Hyeon Lee; Tae-Shin Kim; Tack-Hoon Kim; Hee-Dong Park; Jin-Seok Byun; Min-Chul Kim; Won-Il Jeong; Diego F Calvisi; Jin-Man Kim; Dae-Sik Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

Review 8.  Stem cell-based regenerative opportunities for the liver: State of the art and beyond.

Authors:  Eleftheria Tsolaki; Evangelia Yannaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

9.  Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity.

Authors:  Esperanza Gonzalez; Sebastiaan van Liempd; Javier Conde-Vancells; Virginia Gutierrez-de Juan; Miriam Perez-Cormenzana; Rebeca Mayo; Agustin Berisa; Cristina Alonso; Cesar A Marquez; Jonathan Barr; Shelly C Lu; Jose M Mato; Juan M Falcon-Perez
Journal:  Metabolomics       Date:  2011-07-14       Impact factor: 4.290

10.  Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC.

Authors:  Diana Becker; Ioannis Sfakianakis; Markus Krupp; Frank Staib; Aslihan Gerhold-Ay; Anja Victor; Harald Binder; Maria Blettner; Thorsten Maass; Snorri Thorgeirsson; Peter R Galle; Andreas Teufel
Journal:  Mol Cancer       Date:  2012-08-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.